Legal Representation
Attorney
Ben Natter
USPTO Deadlines
Next Deadline
399 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20210119)
Due Date
January 19, 2027
Grace Period Ends
July 19, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
34 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 19, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| May 19, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 19, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 19, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 19, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| May 19, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jan 19, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 17, 2020 | DP1B | I | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | Loading... |
| Oct 26, 2020 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED | Loading... |
| Dec 17, 2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 28, 2020 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Oct 26, 2020 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Oct 26, 2020 | D1BR | I | TEAS DELETE 1(B) BASIS RECEIVED | Loading... |
| Jul 7, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 12, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 12, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 22, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 6, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 20, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 19, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 19, 2020 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Feb 11, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Feb 11, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Feb 11, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jan 14, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 14, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 13, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Dec 19, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 12, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 12, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 12, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 11, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 1, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 24, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemicals for use in industry and science, excluding nanomaterial-based chemicals; biochemicals, namely, polypeptides and antibodies for scientific, laboratory or research purposes; biochemicals, namely, polypeptides and antibodies for use in the manufacture of pharmaceuticals and drugs; biochemicals, namely, ion channel blocking antibodies for scientific, laboratory or research purposes; biochemicals, namely, ion channel blocking antibodies for use in the manufacture of pharmaceuticals and drugs; biochemicals, namely, antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; biochemicals, namely, antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
Class 005
Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with ion channel activity; drug delivery agents in the form of liquid preparations for infusion or injection that facilitate the delivery of pharmaceutical preparations; antibodies for medical use, namely, ion channel blocking antibodies and antibodies derived from mini-protein toxins; pharmaceuticals and pharmaceutical preparations incorporating antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins, for the treatment of diseases and conditions associated with ion channel activity
Class 042
Scientific and technological services, namely, scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel blocking antibodies and antibodies derived from mini-protein toxins; drug discovery services and pharmaceutical drug development services; conducting or providing research and development services for others in the field of antibodies; scientific laboratory services relating to the production of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins
Class 044
Medical services; medical services connected with the treatment of diseases through the use of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid
Additional Information
Pseudo Mark
KNOT BODY
Classification
International Classes
001
005
042
044